News GSK reaches $2.2bn deal to buy food allergy biotech RAPT GSK has made its first major acquisition under new CEO Luke Miels, buying RAPT Therapeutics and its food allergy prevention drug ozureprubart.
News Nine more companies sign pricing deals with Trump Nine more pharma groups have agreed to lower the costs of medicines in the US under the Trump administration's most favoured nation (MFN) scheme.
News As year-end nears, pharma groups plump up their pipelines Bristol Myers Squibb, Sanofi, Pfizer, Roche, and Yarrow Bioscience all added to their pipelines this week in an end-of-year licensing deal flurry.
News OMass attracts $420m Roche wager on IBD programme UK biotech OMass has revealed its first major pharma partnership, with Roche paying $20m upfront for an inflammatory bowel disease programme.
News Roche breaks ground on US manufacturing facility Roche's Genentech unit has started work on a $700m manufacturing facility in North Carolina, part of a promised $50bn US investment programme.
Market Access Biotech opportunities in North Carolina, with Kyle Touchston... From BIO 2025: Kyle Touchstone, director of Economic Development Raleigh and Laura Rowley, director of life sciences development for NCBiotech.
News Chiesi signs $1.9bn deal to buy KalVista and its HAE drug Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.